```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1654MCG

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  3  NOV 26  MARPAT enhanced with FSORT command
 NEWS  4  NOV 26  CHEMSAFE now available on STN Easy
 NEWS  5  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS  6  DEC 01  ChemPort single article sales feature unavailable
 NEWS  7  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS  8  DEC 17  Fifty-one pharmaceutical ingredients added to PS
 NEWS  9  JAN 06  The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10  JAN 07  WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                  Classification Data

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:02:00 ON 21 JAN 2009

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 19:02:24 ON 21 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JAN 2009 HIGHEST RN 1094597-78-0
DICTIONARY FILE UPDATES: 20 JAN 2009 HIGHEST RN 1094597-78-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s
kakagagsatlsmayagarfvfslvdamngkegvvecsfvksqetectyfstplllgkkgieknlgigkvssfeekmisdaipe
lkasikkgedfvktlk/sqsp
L1   27 KAKAGAGSATLSMAYAGARFVFSLVDAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKGIEKN
               LGIGKVSSFEEKMISDAIPELKASIKKGEDFVKTLK/SQSP

=> caplus
L2   0 CAPLUS

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   38.54   38.76

FILE 'CAPLUS' ENTERED AT 19:04:20 ON 21 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Jan 2009 VOL 150 ISS 4
FILE LAST UPDATED: 20 Jan 2009 (20090120/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> l1
L3          22 L1

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4           22 DUP REM L3 (0 DUPLICATES REMOVED)

=> d ibib abs total hitstr

L4   ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:674976  CAPLUS
DOCUMENT NUMBER:          149:27434
TITLE:                    Biomarkers for diagnosis, grading, and therapeutic
                          monitoring of pancreatic diseases including carcinoma,
                          ductal adenocarcinoma, intraepithelial neoplasm,
                          endocrine tumor, and chronic pancreatitis.
INVENTOR(S):              Meyer, Helmut; Schmiegel, Wolff; Sitek, Barbara;
                          Stuehler, Kai; Sipos, Bence; Kloeppel, Guenter;
                          Alkatout, Ibrahim; Hahn, Stephan
PATENT ASSIGNEE(S):       Germany
SOURCE:                   PCT Int. Appl., 45pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2008064670         A2    20080605    WO 2007-DE2174          20071203
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB,
             GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
             KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG,
             MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
             RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
     DE 102006056784       A1    20080605    DE 2006-102006056784    20061201
PRIORITY APPLN. INFO.:                       DE 2006-102006056784A   20061201
AB   The invention relates to methods for diagnosing pancreatic cancer (PaCa)
     or the precursor diseases and/or concomitant diseases thereof, in
     particular pancreatic ductal adenocarcinoma (PDAC), pancreatic
     intraepithelial neoplasia (PanIN), pancreatic lesions, chronic
     pancreatitis (CP), including endocrine pancreatic tumors.  Also disclosed
     is a set of protein biomarkers, with which the diagnoses are performed
     using selected biomarkers from this set.  The invention further relates to
     biomarker combinations suitable for carrying out said method, particularly
     for in vitro diagnosis.
IT   1030396-05-4 1030396-57-6 1030396-73-6
     1030396-75-8
     RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (amino acid sequence; biomarkers for diagnosis, grading, and
        therapeutic monitoring of pancreatic diseases including carcinoma,
        ductal adenocarcinoma, intraepithelial neoplasm, endocrine tumor, and
        chronic pancreatitis)
RN   1030396-05-4  CAPLUS
```

CN Dehydrogenase, malate (human mitochondria-associated) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 1030396-57-6 CAPLUS
CN Dehydrogenase, malate (human mitochondria-associated precursor) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 1030396-73-6 CAPLUS
CN Dehydrogenase, malate (human gene MDH2 isoenzyme 2) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 1030396-75-8 CAPLUS
CN Dehydrogenase, malate (human gene MDH-2 mitochondria-associated isoenzyme 2 precursor) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1099889 CAPLUS
DOCUMENT NUMBER: 149:325085
TITLE: Nonviral vectors for delivering polynucleotides to plants
INVENTOR(S): Khan, Shaharyar
PATENT ASSIGNEE(S): Gencia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 25pp., Cont.-in-part of U.S. Ser. No. 972,963.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080222750	A1	20080911	US 2007-930892		20071031
US 20050147993	A1	20050707	US 2004-972963		20041025
PRIORITY APPLN. INFO.:			US 2003-513983P	P	20031024
			US 2004-568436P	P	20040505
			US 2004-972963	A2	20041025

AB Non-viral polynucleotide delivery vehicles and methods of their use are provided. In general, modified polynucleotide-binding proteins are provided comprising a protein transduction domain operably linked to a targeting signal, for example, a non-nuclear organelle targeting signal. One example provides a polypeptide comprising at least one HMG box domain from TFAM (mitochondrial transcription factor A), more typically at least two HMG box domains, and optionally at least one protein transduction domain from Tat transcription factor. The polypeptide can associate with a polynucleotide causing the polynucleotide to condense. The polypeptide can also coat the polynucleotide. Coating and/or condensing the polynucleotide helps protect the polynucleotide from degradation The protein transduction domain helps the polypeptide-polynucleotide complex cross membranes and enter the interior of a cell or an organelle. The targeting signal helps direct the complex to a site of interest and thereby deliver the polynucleotide. The compns. can be used to deliver polynucleotides to specific locations within a plant cell, including but not limited to plastids, plant mitochondria, and plant nuclei. The polynucleotide can also expression addnl. polypeptides, e.g., a biosynthetic protein(s) or an protein(s) that compensates for resistance to environmental stress.
IT 1053487-90-3D, fusion protein with protein transduction domain and HMG box domain
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological

study); USES (Uses)
(use of mitochondrial localization signal from; nonviral vectors for delivering polynucleotides to plants)
RN 1053487-90-3 CAPLUS
CN Dehydrogenase, malate (human mitochondria-associated isoenzyme 2 precursor) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:422254 CAPLUS
DOCUMENT NUMBER: 147:162532
TITLE: Genetic differentiation of six populations of six species of Acridoidea
AUTHOR(S): Ma, Xi-ping; Li, Cui-lan; Guo, Ya-ping; Ma, En-bo
CORPORATE SOURCE: School of Life Science and Technology, Shanxi University, Taiyuan, 030006, Peop. Rep. China
SOURCE: Shanxi Daxue Xuebao, Ziran Kexueban (2007), 30(1), 90-94
CODEN: SDXKDT; ISSN: 0253-2395
PUBLISHER: Shanxi Daxue Xuebao Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB The genetic structure and differentiation of 6 populations of 6 locust species (Locusta migratoria manilensis, Epacromius coerulipes, Oxya chinensis, Acrida cinerea, Oedaleus asiaticus and O. infernalis) were analyzed using horizontal starch gel electrophoresis. Among 13 loci, G3pdh and Mdh-2 were monomorphic across all 6 populations (0.95 criterion), whereas more than one alleles were present at the rest loci in at least one population. Five loci (Gpi, Hk-1, Hk-2, Mdph and Pgm) were highly polymorphic in all six populations (0.95 criterion), each with at least two alleles. The genotype frequency at most loci significantly deviated from the Hardy-Weinberg equilibrium except for Gpi and Mdh-1 in most samples ($P<0.05$). The data of A, P, Ho and He of six species suggested that lowest genetic polymorphism was observed in Acrida chinensis population (A = 2.1, P = 42.6%, Ho = 0.165, and He = 0.191), followed by O. asiaticus and O. infernalis. L. migratoria manilensis, E. coerulipes and O. chinensis possessed higher genetic polymorphism at 13 allozyme loci. The results of cluster anal. by using unweighted pair-group method with arithmetic averaging (UPGMA) based on Roger's genetic distance were consistent with the results obtained from karyotypic anal. It was suggested that the allozyme anal. was a useful mol. marker for phylogenetic reconstruction.
IT 480737-78-8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(genetic differentiation of six populations of six species of Acridoidea)
RN 480737-78-8 CAPLUS
CN Malate dehydrogenase 2 (human clone MGC:3559 IMAGE:2823443) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:979808 CAPLUS
DOCUMENT NUMBER: 145:350610
TITLE: Protein sequences of mitochondria targeting protein and nonviral vectors for delivering polynucleotides
INVENTOR(S): Khan, Shaharyar
PATENT ASSIGNEE(S): Gencia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 42pp., Cont.-in-part of U.S. Ser. No. 972,963.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20060211647	A1	20060921	US 2006-389432		20060324
US 20050147993	A1	20050707	US 2004-972963		20041025
PRIORITY APPLN. INFO.:			US 2003-513983P	P	20031024
			US 2004-568436P	P	20040505
			US 2004-972963	A2	20041025

AB Methods and compns. for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein TFAM comprising a protein transduction domain operably linked to a mitochondria targeting signal is used for mitochondria transfection. A TFAM polypeptide comprising HMG box domain and optionally at least one protein transduction domain. The protein transduction domain helps the polypeptide-polynucleotide complex cross membranes and enter the interior of a cell or an organelle. The targeting signal helps direct the complex to a site of interest and thereby deliver the polynucleotide. Methods for modifying the genome of non-nuclear organelles are also provided.

IT 910078-84-1
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; protein sequences of mitochondria targeting protein and nonviral vectors for delivering polynucleotides)
RN 910078-84-1 CAPLUS
CN Transcription factor mtTFA (mitochondrial transcription factor A)(human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1075909 CAPLUS
DOCUMENT NUMBER: 143:361217
TITLE: Cloning of human solid cancer antigens, and use for cancer diagnosis and therapy
INVENTOR(S): Shimada, Hideaki; Tomonaga, Takeshi; Hiwasa, Takaki; Matsushita, Kazuyuki; Ochiai, Takenori; Nomura, Fumio; Takiguchi, Masaki
PATENT ASSIGNEE(S): Medical Biological Laboratories Co., Ltd., Japan
SOURCE: PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005093063	A1	20051006	WO 2005-JP6222	20050324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1739173 A1 20070103 EP 2005-727480 20050324
R: DE, FR, GB

US 20080219981 A1 20080911 US 2006-594771 20060929

PRIORITY APPLN. INFO.: JP 2004-95732 A 20040329
WO 2005-JP6222 W 20050324

AB This invention provides novel antigens useful in diagnosing solid tumors, encoding cDNAs, antibodies against these antigens and a method of diagnosing cancer using the same. Diagnostic kits comprising antibodies, probe or primer set for detecting those proteins or genes are also provided. Use of antibodies for cancer therapy is claimed. Twenty antigens not previously known to be tumor antigens were identified from colon cancer patients by two-dimensional electrophoresis and 19 antigens were identified from esophagus cancer patients by SEREX.

IT 866166-39-4, malate dehydrogenase 2 (human)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; cloning of human solid cancer antigens, and use for cancer diagnosis and therapy)

RN 866166-39-4 CAPLUS

CN malate dehydrogenase 2 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:547694 CAPLUS

DOCUMENT NUMBER: 143:91999

TITLE: Delivery of transforming nucleic acids to organelles as complexes with nucleic acid-binding proteins

INVENTOR(S): Khan, Shaharyar

PATENT ASSIGNEE(S): Gencia Corporation, USA

SOURCE: PCT Int. Appl., 466 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056752	A2	20050623	WO 2004-US35137	20041025
WO 2005056752	A3	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004297533	A1	20050623	AU 2004-297533	20041025
CA 2543257	A1	20050623	CA 2004-2543257	20041025
EP 1687017	A2	20060809	EP 2004-817807	20041025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

JP 2007508846 T 20070412 JP 2006-536845 20041025
PRIORITY APPLN. INFO.: US 2003-513983P P 20031024
US 2004-568436P P 20040505
WO 2004-US35137 W 20041025

AB Methods and compns. for delivering transforming nucleic acids to target organelles as complexes with nucleic acid-binding proteins are described. The nucleic acid binding proteins protect the nucleic acid from nucleases and may include protein transduction domains to promote cellular and organelle uptake of the nucleic acid. The method avoids the need to use viral vectors for the delivery of transforming of nucleic acids and can be used to modify organelle genomes in the gene therapy of diseases associated with mutations in organelle genomes. A protein containing the protein transduction domain of tat protein, and the mitochondrial localization signal of the TFAM mitochondrial transcription factor was manufactured by expression of the gene in Escherichia coli. Complexes of this protein with a green fluorescent protein reporter gene were rapidly imported into the mitochondria of SH-5Y5Y cells. When the mitochondrial targeting signal was replaced with the nuclear localization signal of large T antigen, the transforming DNA was transported to the nucleus.

IT 855805-82-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence, mitochondrial targeting peptide of; delivery of transforming nucleic acids to organelles as complexes with nucleic acid-binding proteins)

RN 855805-82-2 CAPLUS
CN Dehydrogenase, malate (human clone WO2005/056752-SEQID-96 mitochondria-associated gene MDH2 precursor fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:681680 CAPLUS
DOCUMENT NUMBER: 141:200162
TITLE: Mitochondrial malate dehydrogenase DNA fragmentation activator fragment and related conjugated proteins and antibodies for cancer therapy
INVENTOR(S): Wright, Susan C.; Larrick, James W.; Nock, Steffen R.; Wilson, David S.
PATENT ASSIGNEE(S): Palo Alto Institute of Molecular Medicine, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004070012	A2	20040819	WO 2004-US2974	20040202
WO 2004070012	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,

MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2004209644	A1	20040819	AU 2004-209644	20040202
CA 2514841	A1	20040819	CA 2004-2514841	20040202
US 20040191843	A1	20040930	US 2004-770668	20040202
EP 1590440	A2	20051102	EP 2004-707424	20040202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006522021	T	20060928	JP 2006-503266	20040202

PRIORITY APPLN. INFO.:	US 2003-444191P	P 20030203
	US 2003-460855P	P 20030408
	US 2004-770668	A 20040202
	WO 2004-US2974	W 20040202

AB The invention provides compns. comprising amino acid sequences that have cell killing activity, nucleic acid sequences encoding them, antibodies that specifically bind with them, and methods of using these compns. for increasing and/or reducing cell death, detecting cell death, diagnosing diseases associated with altered cell death, and methods for identifying test agents that alter cell death. More particularly, the invention provides an activator of DNA fragmentation (ADF), a C-terminal fragment of mitochondrial MDH (malate dehydrogenase), which can induce DNA fragmentation by activating nuclease endogenous to normal nuclei. The invention also provides a conjugate comprising a cell death-inducing mol. (such as ADF) and a cell mol.-recognizing compound, and use of said conjugate in killing cancer cells. Specifically, the invention relates that conjugate can be composed of said ADF and/or other mitochondrial/non-mitochondrial cell death-inducing proteins (such as Htra/Omi, apoptosis inducing factor, Smac/DIABLO, EndoG, Nix, Nip3, CIDE-B, gelsolin, Bcl-2, Bax, Bad, Bid, caspase-activated DNase, DNase I or DNase II), and that cell mol.-recognizing compds. can include antibodies or growth factors. In particular embodiments, recombinant ADF proteins, ADF-Ant (antennapedia) and rADF-bFGF, are shown to be cytotoxic to a variety to tumor cell types, and even drug-resistant cancer cell lines.

IT 742220-09-3P 742220-13-9P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; mitochondrial malate dehydrogenase DNA fragmentation activator fragment and related conjugated proteins and antibodies for cancer therapy)

RN 742220-09-3 CAPLUS
CN Dehydrogenase, malate (human mitochondria gene MDH precursor) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 742220-13-9 CAPLUS
CN Dehydrogenase, malate (human mitochondria gene MDH ADF (activator of DNA fragmentation) fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2004:681539 CAPLUS
DOCUMENT NUMBER:	141:212819
TITLE:	Compounds useful in coating stents to prevent and treat stenosis and restenosis
INVENTOR(S):	Wang, Yuqiang; Larrick, James W.; Wright, Susan C.
PATENT ASSIGNEE(S):	Medlogics Device Corporation, USA
SOURCE:	PCT Int. Appl., 63 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004069201	A2	20040819	WO 2004-US3143		20040203
WO 2004069201	A3	20050519			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20070037739	A1	20070215	US 2006-544241		20060103
PRIORITY APPLN. INFO.:			US 2003-444391P	P	20030203
			WO 2004-US3143	W	20040203

OTHER SOURCE(S): MARPAT 141:212819

AB At least one bioactive agent is locally delivered to a location where a stent is implanted within a lumen in a patient's body. The bioactive agent includes DNA minor groove binder (such as CC-1065 or Duocarmycin); apocynin; RGD peptide (such as RGDfV); stilbene compound (such as resveratrol); camptothecin; des-aspartate angiotensin I; or ADF; or an analog or derivative thereof; or a combination or blend thereof with at least one other bioactive agent. The bioactive agent is generally locally delivered, such as by elution from the stent. The compds. and methods are of particular benefit for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, occlusive disease, or other abnormal lumenal cellular proliferation condition.

IT 740984-82-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. useful in coating stents for local therapy)

RN 740984-82-1 CAPLUS

CN Dehydrogenase, malate (human mitochondria gene MDH 100-amino acid ADF (apoptosis DNA factor) fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:515644 CAPLUS
DOCUMENT NUMBER: 141:65052
TITLE: Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
INVENTOR(S): Mulligan, George; Bryant, Barbara M.; Morrissey, Michael P.; Bolt, Andrew; Damokosh, Andrew I.
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004053066 A2 20040624 WO 2003-US38539 20031204
WO 2004053066 A3 20060908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2508348 A1 20040624 CA 2003-2508348 20031204
AU 2003298873 A1 20040630 AU 2003-298873 20031204
US 20040156854 A1 20040812 US 2003-728055 20031204
EP 1581629 A2 20051005 EP 2003-796633 20031204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006517093 T 20060720 JP 2004-559278 20031204
MX 2005PA05923 A 20050921 MX 2005-PA5923 20050602
PRIORITY APPLN. INFO.: US 2002-431514P P 20021206
WO 2003-US38539 W 20031204

AB The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clin. responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clin. setting.

IT 480737-78-8
RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; methods for identification, assessment, and treatment of patients with proteasome inhibition therapy)
RN 480737-78-8 CAPLUS
CN Malate dehydrogenase 2 (human clone MGC:3559 IMAGE:2823443) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:371153 CAPLUS
DOCUMENT NUMBER: 140:371494
TITLE: Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 886 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2004038376 A2 20040506 WO 2003-US33946 20031024
WO 2004038376 A3 20040826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2004038376 A2 20040506 WO 2003-XA33946 20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

WO 2004038376 A2 20040506 WO 2003-XB33946 20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

AU 2003290537 A1 20040513 AU 2003-290537 20031024
US 20050170528 A1 20050804 US 2003-692002 20031024
EP 1579383 A2 20050928 EP 2003-783074 20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:

US 2002-420729P	P	20021024
US 2002-421062P	P	20021025
US 2002-421102P	P	20021025
US 2002-424701P	P	20021108
US 2002-424715P	P	20021108
US 2002-424718P	P	20021108
US 2002-425256P	P	20021112
US 2003-448461P	P	20030221
US 2003-448462P	P	20030221
US 2003-457877P	P	20030327
US 2003-458373P	P	20030331
WO 2003-US33946	A	20031024

AB The statistical anal. described and claimed is a predictive statistical tree model that overcomes several problems observed in prior statistical models and regression analyses, while ensuring greater accuracy and predictive capabilities. Although the claimed use of the predictive statistical tree model described herein is directed to the prediction of a disease in individuals, the claimed model can be used for a variety of applications including the prediction of disease states, susceptibility of disease states or any other biol. state of interest, as well as other applicable non-biol. states of interest. This model first screens genes to reduce noise, applies kmeans correlation-based clustering targeting a large number of clusters, and then uses singular value decompns. (SVD) to extract the single dominant factor (principal component) from each cluster. This generates a statistically significant number of cluster-derived singular factors, that are referred to as metagenes, that characterize multiple

patterns of expression of the genes across samples. The strategy aims to extract multiple such patterns while reducing dimension and smoothing out gene-specific noise through the aggregation within clusters. Formal predictive anal. then uses these metagenes in a Bayesian classification tree anal. This generates multiple recursive partitions of the sample into subgroups (the 'leaves' of the classification tree), and assocs. Bayesian predictive probabilities of outcomes with each subgroup. Overall predictions for an individual sample are then generated by averaging predictions, with appropriate wts., across many such tree models. The model includes the use of iterative out-of-sample, cross-validation predictions leaving each sample out of the data set one at a time, refitting the model from the remaining samples and using it to predict the hold-out case. This rigorously tests the predictive value of a model and mirrors the real-world prognostic context where prediction of new cases as they arise is the major goal.

IT 480924-12-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; binary prediction tree modeling with many predictors and its uses in clin. and genomic applications)

RN 480924-12-7 CAPLUS
CN Malate dehydrogenase precursor (human gene MDH) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:308357 CAPLUS
DOCUMENT NUMBER: 140:333596
TITLE: Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor
INVENTOR(S): Wu, Thomas D.; Zhang, Zemin; Zhou, Yan
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 7273 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030615	A2	20040415	WO 2003-US28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500687	A1	20040415	CA 2003-2500687	20030929
WO 2004030615	A2	20040415	WO 2003-XA28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003295328	A1	20040423	AU 2003-295328		20030929
EP 1594447	A2	20051116	EP 2003-786510		20030929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006516089	T	20060622	JP 2004-541530		20030929
US 20070224201	A1	20070927	US 2005-529351		20050325
PRIORITY APPLN. INFO.:			US 2002-414971P	P	20021002
			WO 2003-US28547	W	20030929

AB The present invention provides a large number of specific cDNA sequences which are upregulated in certain tumor tissues as compared to their normal tissue counterparts and therefore useful for the diagnosis and treatment of tumor in mammals. An expressed sequence tag (EST) DNA database was searched and interesting EST sequences identified by GEPIS (gene expression profiling in silico), a bioinformatics tool that characterizes genes of interest for new cancer therapeutic targets. Using this type of screening bioinformatics, various tumor-associated antigenic target (TAT) proteins (and their encoding nucleic acid mols). were identified as being significantly overexpressed in particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 677802-87-8P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor)

RN 677802-87-8 CAPLUS
CN Tumor-associated antigen PRO81558 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:85983 CAPLUS
DOCUMENT NUMBER: 140:194431
TITLE: Human prostate cancer marker genes associated with various metastatic stages identified by gene profiling, and related compositions, kits, and methods for diagnosis, prognosis and therapy
INVENTOR(S): Schlegel, Robert; Endege, Wilson O.
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 131 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20040009481	A1	20040115	US 2002-166883		20020611
US 20040009481	A1	20040115	US 2002-166883		20020611
PRIORITY APPLN. INFO.:			US 2001-297285P	P	20010611
			US 2002-166883	A	20020611

AB The invention relates to compns., kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A

variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer. In particular, three sets of the marker genes, corresponding to 11617 GenBank Accession Nos. (only 2168 new submissions) and 15 SEQ IDs, are identified by transcription profiling using RNA derived from clin. samples, that were expressed at least 2-fold or greater than the normal controls. Using TNM staging approach, these markers are divided to three groups, ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the liver (M stage); ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the bone (M stage); and ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the lymph nodes (N stage and/or M stage). The invention also relates to a kit for assessing the specific type of metastatic prostate cancer, e.g., cancer that has metastasized to the liver, bone or lymph nodes. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 480924-12-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human prostate cancer marker genes associated with various metastatic stages identified by gene profiling, and related compns., kits, and methods for diagnosis, prognosis and therapy)

RN 480924-12-7 CAPLUS
CN Malate dehydrogenase precursor (human gene MDH) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:935003 CAPLUS
DOCUMENT NUMBER: 142:1547
TITLE: The status, quality, and expansion of the NIH full-length cDNA project: The mammalian gene collection (MGC)
AUTHOR(S): Gerhard, Daniela S.; Wagner, Lukas; Feingold, Elise A.; Shenmen, Carolyn M.; Grouse, Lynette H.; Schuler, Greg; Klein, Steven L.; Old, Susan; Rasooly, Rebekah; Good, Peter; Guyer, Mark; Peck, Allicon M.; Derge, Jeffery G.; Lipman, David; Collins, Francis S.
CORPORATE SOURCE: The MGC Project Team, NIH, USA
SOURCE: Genome Research (2004), 14(10b), 2121-2127
CODEN: GEREFS; ISSN: 1088-9051
PUBLISHER: Cold Spring Harbor Laboratory Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The National Institutes of Health's Mammalian Gene Collection (MGC) project was designed to generate and sequence a publicly accessible cDNA resource containing a complete open reading frame (ORF) for every human and mouse gene. The project initially used a random strategy to select clones from a large number of cDNA libraries from diverse tissues. Candidate clones were chosen based on 5'-EST sequences, and then fully sequenced to high accuracy and analyzed by algorithms developed for this project. Currently, more than 11,000 human and 10,000 mouse genes are represented in MGC by at least one clone with a full ORF. The random selection approach is now reaching a saturation point, and a transition to protocols targeted at the missing transcripts is now required to complete the mouse and human collections. Comparison of the sequence of the MGC clones to reference genome sequences reveals that most cDNA clones are of very high sequence quality, although it is likely that some cDNAs may carry missense variants as a consequence of exptl. artifact, such as PCR, cloning, or reverse transcriptase errors. Recently, a rat cDNA component was added to

the project, and ongoing frog (Xenopus) and zebrafish (Danio) cDNA projects were expanded to take advantage of the high-throughput MGC pipeline. The sequence data for the full-length clones from this study have been submitted to GenBank/EMBL/DDBJ under accession nos. BC000001-BC077073. [This abstr record is one of 39 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 480737-78-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; status, quality, and expansion of NIH full-length cDNA project and mammalian gene collection (MGC))

RN 480737-78-8 CAPLUS

CN Malate dehydrogenase 2 (human clone MGC:3559 IMAGE:2823443) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:942764 CAPLUS

DOCUMENT NUMBER: 140:3792

TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics

INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal

PATENT ASSIGNEE(S): Duke University, USA

SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XA38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:		
US 2002-374547P	P	20020423
US 2002-420784P	P	20021024
US 2002-421043P	P	20021025
US 2002-424680P	P	20021108
WO 2002-US38221	A	20021112

AB Genes whose expression is correlated with an determinant of an

atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal.

IT 480924-12-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics)

RN 480924-12-7 CAPLUS
CN Malate dehydrogenase precursor (human gene MDH) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:837371 CAPLUS
DOCUMENT NUMBER: 139:333132
TITLE: Targets for therapeutic intervention identified in the human mitochondrial proteome
INVENTOR(S): Ghosh, Soumitra S.; Fahy, Eoin D.; Zhang, Bing; Gibson, Bradford W.; Taylor, Steven W.; Glenn, Gary M.; Warnock, Dale E.
PATENT ASSIGNEE(S): Mitokor Inc., USA; The Buck Institute for Age Research
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003087768	A2	20031023	WO 2003-US10870		20030404
WO 2003087768	A3	20051124			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003223520	A1	20031027	AU 2003-223520		20030404
US 20040101874	A1	20040527	US 2003-408765		20030404
PRIORITY APPLN. INFO.:			US 2002-372843P	P	20020412
			US 2002-389987P	P	20020617
			US 2002-412418P	P	20020920
			WO 2003-US10870	W	20030404

AB Mitochondrial targets for drug screening assays and for therapeutic intervention in the treatment of diseases associated with altered mitochondrial function are provided. Complete amino acid sequences are provided for 3025 polypeptides that comprise the human heart mitochondrial proteome, using fractionated proteins derived from highly purified mitochondrial prepns., to identify previously unrecognized mitochondrial mol. components. Oxidative post-translational modification of tryptophan residues to N-formylkynurenine in cardiac mitochondrial proteins is also

demonstrated by mass spectrometry.
IT 612108-03-9 612123-33-8
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; targets for therapeutic intervention identified in the human mitochondrial proteome)
RN 612108-03-9 CAPLUS
CN Protein (human heart clone GenBank gi:5174541 mitochondria-associated) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 612123-33-8 CAPLUS
CN Protein (human heart clone GenBank gi:14782063 mitochondria-associated) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:356640 CAPLUS
DOCUMENT NUMBER: 138:380471
TITLE: Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses
INVENTOR(S): Brissette, William H.; Neote, Kuldeep S.; Zagouras, Panayiotis; Zenke, Martin; Lemke, Britt; Hacker, Christine
PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer Molekulare Medizin
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038130	A2	20030508	WO 2002-US34888	20021031
WO 2003038130	A3	20040212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2460283	A1	20030508	CA 2002-2460283	20021031
WO 2003038130	A2	20030508	WO 2002-XA34888	20021031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				

NE, SN, TD, TG

AU 2002363139	A1	20030512	AU 2002-363139	20021031
US 20040014064	A1	20040122	US 2002-285366	20021031
EP 1446507	A2	20040818	EP 2002-798424	20021031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005531280	T	20051020	JP 2003-540394	20021031
MX 2004PA03382	A	20041122	MX 2004-PA3382	20040412
PRIORITY APPLN. INFO.:			US 2001-335048P	P 20011031
			US 2001-335183P	P 20011102
			WO 2002-US34888	W 20021031

AB The present invention provides mol. targets that regulate erythropoiesis. Groups of genes or their encoded gene products comprise panels of the invention and may be used in therapeutic intervention, therapeutic agent screening, and in diagnostic methods for diseases and/or disorders of erythropoiesis. The panels were discovered using gene expression profiling of erythroid progenitors with Affymetrix HU6800 and HG-U95Av2 chips. Cells from an in vitro growth and differentiation system of SCF-Epo dependent human erythroid progenitors, E-cadherin+/CD36+ progenitors, cord blood, or CD34+ peripheral blood stem cells were analyzed. The HU6800 chip contains probes from 13,000 genes with a potential role in cell growth, proliferation, and differentiation and the HG-U95Av2 chip contains 12,000 full-length, functionally-characterized genes. This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

IT 480924-12-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses)

RN 480924-12-7 CAPLUS

CN Malate dehydrogenase precursor (human gene MDH) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:448587 CAPLUS
Correction of: 2003:177120

DOCUMENT NUMBER: 139:18398
Correction of: 138:200022

TITLE: Differentially expressed nucleic acids and their encoded proteins associated with pain and their use in screening for regulatory agents

INVENTOR(S): Woolf, Clifford; D'Urso, Donatella; Befort, Katia; Costigan, Michael

PATENT ASSIGNEE(S): The General Hospital Corporation, USA; Bayer AG

SOURCE: PCT Int. Appl., 1017 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016475	A2	20030227	WO 2002-XA25765	20020814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				

UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003016475 A2 20030227 WO 2002-US25765 20020814
WO 2003016475 A3 20040910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-312147P P 20010814
US 2001-346382P P 20011101
US 2001-333347P P 20011126
WO 2002-US25765 A 20020814

AB The present invention relates to human and rat nucleic acid sequences which are related to pain and which are differentially expressed during pain. The nucleic acids are differentially expressed by at least ±1.4-fold in any or all of the following conditions using the Affymetrix human U95, murine U74 and rat U34 GeneChip arrays: axotomy, spared nerve injury, chronic construction, spinal segmental nerve lesion, and inflammatory pain models. The invention further relates to methods of identifying nucleic acid sequences which are differentially expressed during pain, microarrays comprising such differentially expressed sequences, and methods of screening agents for the ability to regulate the expression of such differentially expressed sequences. [This abstract record is one of seven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 538439-03-1
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; differentially expressed nucleic acids and their encoded proteins associated with pain and their use in screening for regulatory agents)

RN 538439-03-1 CAPLUS
CN Pain-regulated protein (human clone WO03016475-SEQID-6546) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:786973 CAPLUS
DOCUMENT NUMBER: 137:274808
TITLE: Translational profiling of human cell types by expressed peptide tags and global peptide tags
INVENTOR(S): Chicz, Roman M.; Tomlinson, Andrew J.; Urban, Robert G.
PATENT ASSIGNEE(S): Zycos, Inc., USA
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078524	A2	20021010	WO 2002-US9671	20020328
WO 2002078524	A3	20041125		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG

AU 2002311787	A1	20021015	AU 2002-311787		20020328
US 20040236091	A1	20041125	US 2004-473127		20040617
PRIORITY APPLN. INFO.:			US 2001-279495P	P	20010328
			US 2001-292544P	P	20010521
			US 2001-310801P	P	20010808
			US 2001-326370P	P	20011001
			US 2001-336780P	P	20011204
			US 2002-358985P	P	20020220
			WO 2002-US9671	W	20020328

AB Two hundred thirty-five peptides representative of proteins expressed by a given human cell type and isolated nucleic acids that encode the polypeptides are disclosed. Thus, peptides are identified by immunoaffinity purification of class I and class I HLA mols., followed by acid extraction and solid phase extraction of the EPT (expressed protein tag) repertoire, reversed phase HPLC separation and mass spectrometry anal. Enzymic or chemical digestion strategies to reduce proteins of a complex mixture yields peptides designated global peptide tags (GPT), which are then separated and fractionated by multiple modes of chromatog. and ultimately sequenced by liquid chromatog. online with tandem mass spectrometry. Each peptide is classified according to cell line and HLA type, source protein reference(s), and a function key corresponding to biol. classification(s) such as kinases, phosphatases, proteases and protease inhibitors, transporters, cytoskeletal proteins, receptors, and transcription factors. The compns. and method described can be used to define a cell type at a given developmental, metabolic, or disease stage by identifying and cataloging proteins expressed in the cell. The compns. can also be used in the manufacture of therapeutics as well as in diagnostics and drug screening.

IT 465570-35-8 465570-36-9 465570-37-0
465570-39-2
RL: PRP (Properties)
(unclaimed protein sequence; translational profiling of human cell types by expressed peptide tags and global peptide tags)

RN 465570-35-8 CAPLUS
CN 239: PN: WO02078524 SEQID: 474 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 465570-36-9 CAPLUS
CN 241: PN: WO02078524 SEQID: 476 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 465570-37-0 CAPLUS
CN 242: PN: WO02078524 SEQID: 477 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 465570-39-2 CAPLUS
CN 248: PN: WO02078524 SEQID: 483 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:18945 CAPLUS
DOCUMENT NUMBER: 138:67676
TITLE: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
AUTHOR(S): Strausberg, Robert L.; Feingold, Elise A.; Grouse, Lynette H.; Derge, Jeffery G.; Klausner, Richard D.; Collins, Francis S.; Wagner, Lukas; Shenmen, Carolyn M.; Schuler, Gregory D.; Altschul, Stephen F.; Zeeberg, Barry; Buetow, Kenneth H.; Schaefer, Carl F.; Bhat, Narayan K.; Hopkins, Ralph F.; Jordan, Heather; Moore, Troy; Max, Steve I.; Wang, Jun; Hsieh, Florence; Diatchenko, Luda; Marusina, Kate; Farmer, Andrew A.; Rubin, Gerald M.; Hong, Ling; Stapleton, Mark; Soares, M. Bento; Bonaldo, Maria F.; Casavant, Tom L.; Scheetz, Todd E.; Brownstein, Michael J.; Usdin, Ted B.; Toshiyuki, Shiraki; Carninci, Piero; Prange, Christa; Raha, Sam S.; Loquellano, Naomi A.; Peters, Garrick J.; Abramson, Rick D.; Mullahy, Sara J.; Bosak, Stephanie A.; McEwan, Paul J.; McKernan, Kevin J.; Malek, Joel A.; Gunaratne, Preethi H.; Richards, Stephen; Worley, Kim C.; Hale, Sarah; Garcia, Angela M.; Gay, Laura J.; Hulyk, Stephen W.; Villalon, Debbie K.; Muzny, Donna M.; Sodergren, Erica J.; Lu, Xiuhua; Gibbs, Richard A.; Fahey, Jessica; Helton, Erin; Ketteman, Mark; Madan, Anuradha; Rodrigues, Stephanie; Sanchez, Amy; Whiting, Michelle; Madan, Anup; Young, Alice C.; Shevchenko, Yuriy; Bouffard, Gerard G.; Blakesley, Robert W.; Touchman, Jeffrey W.; Green, Eric D.; Dickson, Mark C.; Rodriguez, Alex C.; Grimwood, Jane; Schmutz, Jeremy; Myers, Richard M.; Butterfield, Yaron S. N.; Krzywinski, Martin I.; Skalska, Ursula; Smailus, Duane E.; Schnerch, Angelique; Schein, Jacqueline E.; Jones, Steven J. M.; Marra, Marco A.
CORPORATE SOURCE: National Cancer Institute, NIH, Bethesda, MD, 20892-2580, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(26), 16899-16903
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The National Institutes of Health Mammalian Gene Collection (MGC) Program is a multiinstitutional effort to identify and sequence a cDNA clone containing a complete ORF for each human and mouse gene. ESTs were generated from libraries enriched for full-length cDNAs and analyzed to identify candidate full-ORF clones, which then were sequenced to high accuracy. The MGC has currently sequenced and verified the full ORF for a nonredundant set of >9000 human and >6000 mouse genes. Candidate full-ORF clones for an addnl. 7800 human and 3500 mouse genes also have been identified. All MGC sequences and clones are available without restriction through public databases and clone distribution networks. [This abstract record is one of eleven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].
IT 480737-78-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; generation and initial anal. of more than 15,000 full-length human and mouse cDNA sequences)
RN 480737-78-8 CAPLUS
CN Malate dehydrogenase 2 (human clone MGC:3559 IMAGE:2823443) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:247341 CAPLUS
Correction of: 2001:676894
DOCUMENT NUMBER: 136:258371
Correction of: 135:237639
TITLE: Nucleic acids and their encoded polypeptides from human tissues
INVENTOR(S): Tang, Y. Tom; Liu, Chenghua; Asundi, Vinod; Xu, Chongjun; Wehrman, Tom; Ren, Feiyan; Ma, Yunqing; Zhou, Ping; Zhao, Qing; Yang, Yonghong; Drmanac, Radoje; Zhang, Jie; Chen, Rui Hong; Xue, Aidong J.; Wang, Jian Rui
PATENT ASSIGNEE(S): Hyseq, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 130
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066689	A2	20010913	WO 2001-US4942	20010305
WO 2001066689	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402293	A1	20010913	CA 2001-2402293	20010305
AU 2001045280	A	20010917	AU 2001-45280	20010305
EP 1261743	A2	20021204	EP 2001-918174	20010305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030180745	A1	20030925	US 2002-251186	20020919
US 20030228584	A1	20031211	US 2002-291172	20021108
US 20040034208	A1	20040219	US 2003-221278	20030619
AU 2007234602	A1	20071213	AU 2007-234602	20071122
PRIORITY APPLN. INFO.:			US 2000-519705 A	20000307
			US 2000-574454 A	20000519
			US 2000-596193 A	20000617
			US 2000-616847 A	20000714
			US 2000-665363 A	20000919
			US 2000-693267 A	20001020
			WO 2001-US4942 W	20010305
			US 2002-119428 A2	20020409

	US 2002-119926	A1 20020409
	AU 2003-213064	A3 20030214

AB The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof. The present invention provides a collection or library of 188 nucleic acid contig sequences assembled from expressed sequence tag or cDNA libraries isolated mainly by sequencing by hybridization (SBH), standard PCR, Sanger sequencing techniques, and in some cases, sequences obtained form one or more public databases. Tissue sources and nearest neighbor homologies are provided. The invention also relates to the proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

IT 405001-46-9
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

RN 405001-46-9 CAPLUS

CN Protein (human clone WO0166689-SEQID-45-encoded) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:592185 CAPLUS

DOCUMENT NUMBER: 135:177271

TITLE: Cloning, sequencing and therapeutic use of human mitochondrial malate dehydrogenase

INVENTOR(S): Bandman, Olga; Corley, Neil C.; Shah, Purvi

PATENT ASSIGNEE(S): Incyte Genomics, Inc., USA

SOURCE: U.S., 34 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6274138	B1	20010814	US 1997-922957	19970903
US 20020086006	A1	20020704	US 2001-915694	20010725
PRIORITY APPLN. INFO.:			US 1997-922957	A3 19970903

AB This invention relates to nucleic acid and amino acid sequences of a human mitochondrial malate dehydrogenase (MT-MDH). Nucleic acids encoding the MT-MDH of the present invention were first identified in Incyte Clone 11587 from the human peripheral promonocyte cell line cDNA library (THP1PLB01) using a computer search for amino acid sequence alignments. MT-MDH is 294 amino acids in length and has chemical and structural homol. with murine mitochondrial malate dehydrogenase and porcine mitochondrial malate dehydrogenase. Northern anal. shows the expression of this sequence in various libraries. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MT-MDH.

IT 354641-72-8DP, subfragments are claimed
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; cloning, sequencing and therapeutic use of human mitochondrial malate dehydrogenase)

RN 354641-72-8 CAPLUS

CN Dehydrogenase, malate (human Incyte clone 11587 mitochondria-associated) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:666903 CAPLUS
DOCUMENT NUMBER: 133:233618
TITLE: Human cancer-associated gene sequences and polypeptides
INVENTOR(S): Rosen, Craig A.; Ruben, Steven M.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 2352 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000055350	A1	20000921	WO 2000-US5882		20000308
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2366130	A1	20000921	CA 2000-2366130		20000308
EP 1163358	A1	20011219	EP 2000-917770		20000308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2004508001	T	20040318	JP 2000-605767		20000308
US 20020052308	A1	20020502	US 2001-925301		20010810
PRIORITY APPLN. INFO.:			US 1999-124270P	P	19990312
			WO 2000-US5882	W	20000308

AB This invention relates to 842 newly identified cancer-related cDNAs and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such cancer antigens for detection, prevention and treatment of disorders of tissue-specific disorders, particularly the presence of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens, and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue-specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compns. for inhibiting the production and/or function of the polypeptides of the present invention.
IT 292879-76-6
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; human cancer-associated gene sequences and polypeptides)
RN 292879-76-6 CAPLUS
CN Tumor-associated protein (human clone HFPBR03) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=> logoff h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	80.36	119.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-18.04	-18.04

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:11:37 ON 21 JAN 2009